<DOC>
	<DOCNO>NCT02252692</DOCNO>
	<brief_summary>Phase I study healthy adult male female volunteer compare bioavailability enalapril administer orodispersible Minitablets without water comparison standard galenic tablet formulation enalapril . The standard pharmacokinetic parameter calculate bioanalytical result enalapril enalaprilat compare descriptive statistical analysis .</brief_summary>
	<brief_title>Relative Bioavailability Study With Enalapril Healthy Volunteers</brief_title>
	<detailed_description>Trial design : Open label , randomize , 3-way cross-over , 3-treatments , 3-periods 24 healthy male female adult subject . Primary objective : 1 . To assess relative bioavailability 10 mg enalapril administer orodispersible minitablets ( ODMT ) water versus standard enalapril tablet formulation ( reference product : Renitec® 2 x 5 mg tablet ) take water ; 2 . To assess relative bioavailability 10 mg enalapril administer orodispersible minitablets ( ODMT ) disperse oral cavity versus standard enalapril tablet formulation ( reference product : Renitec® 2 x 5 mg tablet ) take water . Secondary objective : 1 . To assess whether PK enalapril affect orodispersible minitablet ( ODMT ) entirely swallow water versus dispersion oral cavity . 2 . To assess general safety tolerability include local tolerability palatability enalapril administer orodispersible minitablet ( ODMT ) .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<criteria>1 . Healthy male female subject age 18 55 year , inclusive . 2 . Body mass index ( BMI ) 18.5 30 kg/m2 inclusive ( BMI = weight/height2 ) . 3 . Nonsmoker ( smoke least 3 month prior screen ) . 4 . Physical examination , clinical laboratory value , vital sign ECGs clinically acceptable investigator . 5 . Subjects must sign informed consent document indicate understand purpose , procedure require study willing participate study comply study procedure restriction . 1 . History evidence clinically significant disorder ( include psychiatric ) , condition disease , opinion investigator would pose risk subject safety interfere study evaluation , procedure , completion . 2 . Women lactating/breastfeeding . 3 . Women plan become pregnant duration study . 4 . Men pregnant partner whose partner plan become pregnant study . 5 . Positive pregnancy test ( woman ) screen predose . 6 . A baseline systolic BP ≥ 140 &lt; 90 mmHg and/or baseline diastolic BP ≥ 90 &lt; 50 mmHg . A baseline ECG QTcB &gt; 440 m ( male ) &gt; 450 m ( female ) heart rate &gt; 100 bpm . 7 . Positive human immunodeficiency virus ( HIV ) antibody , hepatitis B surface antigen , hepatitis C antibodies screen . 8 . Known substance abuse ( eg , alcohol , illicit illegal drug ) within 1 year dosing . 9 . Positive test drug alcohol use screening . If retest screening period negative , subject include . 10 . Inability unwillingness refrain alcohol consumption 24 hour prior study visit limit consumption throughout course study . 11 . Has major surgery , donate lose 500 mL blood within 2 month first study treatment history chronic anemia . 12 . Receiving receive investigational drug ( currently use investigational drug device ) within 30 day 5 halflives ( whichever longer ) , prior receive first study treatment . 13 . Use overthecounter prescription medication within 7 day 5 halflives ( whichever longer ) , prior receive first study treatment . However , subject use medication within 7 day first study drug administration , he/she include study study accord investigator medication relevant within context trial . Paracetamol ( 2 g per day ) analgesia , hormonal birth control medication allow . 14 . Use herbal medicine ( eg . St. John 's wort ) , vitamin , supplement consume subject within 7 day prior receive first study treatment . However , subject use herbal medicine ( eg , St. John 's wort ) , vitamin , supplement medication within 7 day first study drug administration , he/she include study accord investigator medication relevant within context trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Bioavailability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>enalapril</keyword>
	<keyword>enalaprilat</keyword>
</DOC>